Anticipating low-teens EPS growth, though earnings will be weighted toward the second half of the year due to front-loaded tariff impacts in Q1. Management has modeled margins based on a 15% tariff rate, though they have only seen an executive order for 10%. They assume these rates will remain for the rest of the year and note that because the company carries six months of inventory, any rate changes in August would not provide a benefit until 2027. ...

Financial Data and Key Metrics Changes - In Q4 2025, the company reported sales of $751 million, with core sales increasing by 10.8% year-over-year, benefiting from foreign exchange (FX) which added nearly 400 basis points [15][19] - Adjusted EBITDA margin for Q4 was 14.8%, a 90 basis point improvement from the previous year, driven by volume, price, and productivity [16][21] - Adjusted EPS for Q4 was $0.38, up more than 50% from Q4 2024, supported by strong operating profits and share repurchases [13][16] - For the full year 2025, sales reached $2.7 billion, with core sales increasing by 6.5% [17][18] - Adjusted EBITDA for 2025 was up 26%, resulting in a margin of around 14%, a 2-point improvement over 2024 [13][18] Business Line Data and Key Metrics Changes - Specialty products and technologies revenue grew nearly 16% year-over-year, with core sales up 10.9% [22] - The orthodontics business, including Spark, saw high single-digit growth, with brackets and wires up double digits year-over-year [22][24] - The implants segment grew mid-single digits globally, with strong performance in digital and regenerative segments [22] - Equipment and consumables segment core sales increased by 10.7%, with diagnostics core sales up double digits globally [24] Market Data and Key Metrics Changes - The North American diagnostic market returned to growth in the second half of 2025, marking the third consecutive quarter of positive growth across all business lines [31][32] - The overall implant market is estimated to be growing mid-single digits, with the company slightly outperforming this in Q4 [70] Company Strategy and Development Direction - The company is focused on a value creation plan aimed at achieving 2%-4% core growth, 4%-7% EBITDA growth, and 7%-10% EPS growth, with a free cash flow conversion target of 100% or better [7][14] - Continued investment in R&D and new product launches is a priority, with a strong pipeline for 2026 [12][31] - The company aims to maintain its competitive edge by enhancing customer training and product offerings [71] Management's Comments on Operating Environment and Future Outlook - Management noted that the dental market remains slow but stable, with signs of improvement beginning to emerge [31][32] - The company expects core revenue growth of 2%-4% for 2026, aligning with medium-term financial objectives [14][26] - Risks include macroeconomic volatility and uncertainties in the Chinese market, particularly regarding value-based pricing (VBP) [41][54] Other Important Information - The company implemented a $250 million share repurchase program in early 2025, returning over $160 million to shareholders throughout the year [9][25] - Free cash flow for 2025 was $231 million, with a conversion rate of 114% [25] Q&A Session Summary Question: Guidance and potential upsides/risks - Management discussed the guidance for 2026, highlighting potential upsides from market momentum and pricing, while noting risks from macro volatility and the Chinese market [35][41] Question: Tax rate expectations - The expected non-GAAP tax rate for 2026 is around 28%, with potential for further reductions depending on U.S. profitability and debt management [47][49] Question: VBP assumptions for ortho and implants - Management expects first-round VBP for ortho and second-round for implants in 2026, but specific timing remains uncertain [52][54] Question: Spark growth and profitability - Spark continues to outgrow the market, with profitability consistent with previous quarters, driven by new product introductions and customer training [78]

Group 1 - The report highlights sectors with high growth potential and cost-effectiveness, including financials, consumer staples, and technology hardware, with a focus on service consumption and software services in the medium term [1] - The report indicates that the EPS of Chinese listed companies is expected to rise for the third consecutive year in 2025, with a significant rebound in market performance anticipated following improvements in EPS expectations [2][3] - The report emphasizes that the correlation between EPS growth and nominal economic growth is strong, suggesting that structural changes in the stock market and improvements in corporate profitability are crucial for capturing market opportunities [3] Group 2 - The report identifies consumer services, durable goods, and technology hardware as sectors with high ROE levels that are likely to improve further, indicating strong investment potential [7][18] - It notes that sectors such as software services, consumer staples, and household products maintain high levels of cost-effectiveness, while technology hardware and durable goods are not significantly overvalued [7][20] - The report provides a comparative analysis of PEG ratios, indicating that sectors like diversified finance, materials, and durable goods have PEG levels below 1, suggesting attractive valuations [20][23] Group 3 - The report discusses the importance of earnings performance in the context of upcoming earnings disclosures, highlighting that sectors with improved economic conditions provide a solid foundation for market performance [4] - It mentions that the Hong Kong market's liquidity is primarily driven by capital inflows, which are influenced by the market's comparative advantages [3] - The report outlines that the valuation levels of Hong Kong stocks remain attractive compared to global markets, with a current forward PE of around 10x [53][47]

Group 1 - BofA Securities analyst Allen Lutz reiterated a Buy rating on Cardinal Health, Inc. and raised the price forecast from $165 to $170, anticipating strong performance and favorable industry dynamics [1][2] - Cardinal Health is set to host an investor day on June 12, where it will provide an updated business outlook and a roadmap for sustained double-digit EPS growth [1][2] - The company is expected to revise its Pharmaceutical and Specialty Solutions EBIT growth outlook upward, with long-term Pharmaceutical EBIT growth targets potentially increasing from 4-6% to 5-7% or 5-8% [2][3] Group 2 - Cardinal Health's prior scale disadvantage in specialty areas is diminishing, and recent M&A activity could have a more significant growth impact compared to larger competitors [6] - The company plans to update its growth path for the Global Medical Products and Distribution segment, addressing tariff impacts and evolving demand trends [7] - The Other segment has shown solid growth, with potential for sustained high-single-digit EBIT growth, while maintaining a balanced capital allocation strategy [8]